UNSPSC 51281902: Rifabutin

This classification denotes a heat shock protein inhibitor and antineoplastic antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1W306TDA6S. European Medicines Agency schedules Rifabutin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10304MIG. Rifabutin generally arises in the molecular formula C46H62N4O11.

The term RIFABUTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) RIFABUTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rifabutin under HS 29419000 and SITC 54139. As of Q4 2014, RIFABUTIN remains the US FDA Preferred Term for this commodity. Rifabutin bears US NLM identifiers UMLS ID C0140575 and NCI Concept Code C1408.

UNSPSC 51281902 Rifabutin is a Commodity code for a specific tuberculosis antibiotic used in state and local pharmacy benefit programs and health plan formularies. State and local governments purchase rifabutin primarily through their pharmacy benefit management arrangements, group purchasing organizations, and direct pharmaceutical supplier contracts to support Medicaid, employee health plans, and public health initiatives. The code encompasses the supply of this branded or generic pharmaceutical product as part of broader medication procurement and therapeutic management within state health agencies, county health departments, and municipal public health systems. Issuing bodies soliciting under this code include state health and human services departments managing pharmacy benefits for Medicaid and state employee plans, as well as county and municipal health authorities managing communicable disease treatment programs.

The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment and cost management. The RFI requests information from potential vendors regarding their experience with direct contracting for self-insured employers and government health plans, flexibility to negotiate contracts based on negotiated net pricing models, and capability to implement value-based or outcomes-based agreements. No award value, budget range, or formal competitive timeline is specified in the RFI materials, as the state is conducting foundational market intelligence to inform future procurement strategy and specifications for a formal Request for Proposal.